Pharmaceutical Engineering & Drug Delivery

Hear from AccBio Conference keynote speaker Raymond Deshaies about the future of biopharmaceutical development.

Strategies for repurposing existing antiviral drugs, such as modifying how they are  dosed, administered, and delivered, could them an important part of fighting COVID-19 until a vaccine is available.  

Sytems that interact with cell and tissue barriers in the body are being developed to improve therapeutic delivery and promote healing.

The pharmaceutical industry is finding new uses for artificial intelligence (AI) in drug development.

The market for chimeric antigen receptor (CAR) T-cell therapy is projected to be valued at almost $300 million by the end of 2018, and this number is expected to grow annually by 32% for the next decade.

Bob Langer of MIT shares his predictions on where he sees the profession of chemical engineering heading over the next 25 years.

Humans have roughly 40 trillion bacterial cells in their bodies; up to 1,000 species of bacteria live in the human gut alone.

This month, brush up on the essentials of continuous evaporation, learn new uses for hydrofoil impellers, enjoy the special section on translational medicine, and more.

New green catalyst draws attention for its speed and efficiency.

A new report released by the European Centre for Disease Prevention and control (ECDC) emphasizes that antimicrobial resistance remains one of the greatest public health threats today.

An international team of researchers has created new antiviral nanoparticles that show potential for outperforming current antiviral drugs.

2017 Prausnitz Institute Lecturer Rex Reklaitis speaks with long-time Purdue colleague Dr. Rakesh Agrawal.

Microscopic versions of silkworm cocoons that could be used to protect sensitive molecular materials.

The molecular cages show potential for use in energy conversion, drug delivery, and as sensors.

In its first year, BioTM is already topping the charts, with top ratings for viewing, sharing, and discussion of articles.

As we approach ICBE 2017, which begins this weekend in San Diego, we look back at some of the exciting research that figured among 2016's highlights and look forward to the new developments to be unveiled at ICBE 2017.

This special issue focuses on smart and precision medications, presenting novel work aimed at a wide range of medical applications, from diabetes treatments, cancer therapy, tissue engineering, drug delivery, and more.

Tests by researchers at Baylor College of Medicine have recently shown that nanoparticles modified with polyethylene glycol selectively affect specific areas of the immune system, showing potential

A startup in southern California is designing microbes that extend DNA beyond the natural A, T, G, and C components to include X and Y.

Multidrug resistance (MDR) is one of main reasons chemotherapy drugs fail.

The U.S. government announced this week that it is putting aside $55 million to create a public database with health information on about one million volunteers.

Forty healthy volunteers will undergo phase I clinical testing of a Zika DNA vaccine in a few weeks.

One drug company is hoping to collect DNA from 100,000 cancer patients with the goal of matching them with drug companies who could offer the most effective help.

The past few years have been full of stories about how a number of serious conditions could be treated or cured by introducing certain bacteria to the digestive system.

Learn about the work Jeffrey is doing with polymers to help improve drug delivery.

Yesterday an 18-month-old research group called Rubius was officially launched with the mission to genetically engineer red blood cells for dru

The American Institute of Chemical Engineers (AIChE) and its Society for Biological Engineering (SBE), in partnership with John Wiley and Sons, will launch a new quarterly, peer-reviewed, online, o

A group called the Global Alliance for Genomics and Health (known as the Global Alliance)  wants to maximize the use of genetic

This meeting will bring together thought-leaders from the pharmaceutical and biopharmaceutical industries. The meeting's goal is to allow engineers in these industries to assess processes aimed at improving sustainability in their organizations and to both justify their ROI and improve their performance.

One day the capsule you swallow to treat a disease may not deliver medicine but instead may deliver DNA and other biological machinery—essentially a factory that creates medicine on demand.